Michael Hallek
Leads the German CLL Study Group, whose trials (CLL8, CLL14, CLL13) set global standards for CLL treatment.
Michael Hallek chairs the German CLL Study Group and led CLL8 (FCR), CLL14 (venetoclax-obinutuzumab), and CLL13/GAIA, the trials that moved CLL from chemotherapy to fixed-duration targeted therapy.
| Title | Journal | Year |
|---|---|---|
| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions (CLL14) | NEJM | 2019 |
Pages like this
not linked directly; found by shared links- PairingVenetoclax + obinutuzumab (12 months)
Shares CLL14, CLL13 / GAIA, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Obinutuzumab.
- Key paperAMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients
Shares CLL13 / GAIA, Obinutuzumab, CD20, BCL-2.
- TrialAMPLIFY
Shares Obinutuzumab, CD20, BCL-2, Venetoclax.
- TrialGLOW
Shares Obinutuzumab, BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
- Key paperMURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL
Shares CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, CD20, BCL-2, Venetoclax.
- TrialCELESTIAL-TNCLL
Shares Obinutuzumab, BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
- TrialELEVATE-TN
Shares Obinutuzumab, CD20, Chronic lymphocytic leukaemia.
- TermIGHV mutational status
Shares CLL13 / GAIA, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Chronic lymphocytic leukaemia.